Sign inJoin waitlistJoin the waitlist

Oluwadunni Emiloju

Assistant Professor, Department of Hematology and Medical Oncology · Emory University School of Medicine

Credentials: · · · · · · · · ·

History

Emory University School of Medicine
Present

Hematology and Medical Oncology
Mayo Clinic
2021–2024
Internal Medicine
Jefferson Health Medical Education
2017–2020
University College Hospital-Nigeria
2009–2010
UNIV OF IBADAN COLL OF MED, IBADAN, OYO STATE, NIGERIA
2005–2009

Research

Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal Cancer: A Review
Review · JAMA Oncology · 2023 · First of 2 authors · 51 citations
Association Between the Timing of Goals-of-Care Discussion and Hospitalization Outcomes in Patients With Metastatic Cancer
American Journal of Hospice and Palliative Medicine® · 2020 · First of 3 authors · 25 citations
Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer
JCO Precision Oncology · 2024 · First of 14 authors · 13 citations

Frank Sinicrope
6 papers
JH
Joleen Hubbard
5 papers
Claudia Dourado
3 papers
Olatunji Alese
3 papers
Ruoyu Miao
3 papers · 2 as a fellow
SG
Sorab Gupta
3 papers · 3 as a fellow
Christina Wu
2 papers
Cody Eslinger
2 papers · 2 as a fellow
Daniel Ahn
2 papers
Daniel Walden
2 papers · 2 as a fellow
Michael Storandt
2 papers · 2 as a fellow
Mojun Zhu
2 papers

Clinical trials

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Principal investigator · Recruiting · Phase 2
Emory University
2025–2029
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Site PI · Recruiting · Phase 1
Coherus Oncology, Inc.
2025–2028
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2027